EXPOSING the FDA and the USDA - Broad Casting here the things that they would prefer us NOT to know about our FOOD & DRUGS & Farming.

Wednesday, September 21, 2011

RABIES VACCINE, SERIOUS ADVERSE EVENTS - INDIA: REQUEST FOR MORE INFO

***********************************************************************

A ProMED-mail post



ProMED-mail is a program of the

International Society for Infectious Diseases





Date: 21 Sep 2011

Source: Times of India [edited]







Two persons suffered severe respiratory problems and cardiac arrest

after they were injected with an anti-rabies vaccine at the New Delhi

Municipal (NDMC)-run Charak Palika hospital in Moti Bagh on Monday [19

Sep 2011]. [A 45-year-old male] and a [52-year-old female] are in

critical condition and have been shifted to Safdarjung hospital's ICU

ward at present. According to NDMC spokesperson Amit Prasad, all

vaccine vials have been sealed, and a 4-member committee has been

formed to inquire into the matter.



"Prima facie, it appears that an allergic reaction to the drug led to

sudden cardiac arrest and respiratory attack, said a hospital doctor,

who requested not to be named.



Sources said [the 45-year-old male] is an NDMC employee, and [the

52-year-old female] is a housewife living in Moti Bagh. Soon after

being administered the injections, they complained of severe chest

pain and were admitted to the emergency unit of the hospital. A team

of doctors, including cardiologists and anesthetists, tried to revive

them, but when their condition deteriorated further, they were shifted

to Safdarjung hospital.



"My mother had gone to NDMC hospital for the 3rd dose of anti-rabies

vaccine. The vaccine caused sudden cardiac arrest, and her condition

is critical. She is in coma and has been put on a life support

system," claimed Harish, Chandra Devi's son who works with the Delhi

Police. He said that they have filed an FIR against the hospital in

this case.



[The 45-year-old male's] condition is also serious, and he is on

ventilator support. His cousin said that [he] was perfectly fine when

he left the home. "We were informed about his condition almost an hour

later," he said.



According to Dr P K Sharma, the NDMC health officer, anti-rabies

vaccines were given to 12 patients on Monday [19 Sep 2011] including

[the above mentioned individuals]. "All the other patients are fine.

The 2 patients who suffered chest pain and cardiac arrest were given

injections from a new vial. As a preventive measure, we have sealed

all vaccines, and a committee has been formed to inquire into the

matter. Drug reaction from rabies vaccines is extremely rare," he

said.



Sharma added that the expiry date of the vaccines is the year 2013.

NDMC gives anti-rabies vaccines to more than 500 patients every month.

The Municipal Corporation of Delhi (MCD) gives over 10 000 anti-rabies

vaccines monthly. Said Dr V K Monga, Chairman of the MCD health

committee, "I have never come across a case where anti-rabies vaccine

causes such a fatal reaction. Let the committee report come, and if

any problem is found with the particular batch of vaccine, we will

also review our injections."



Another expert said, "The various minor side effects that may develop

during and after a course of anti-rabies treatment includes fever,

headache, insomnia and diarrhoea. Sensitization to proteins contained

in older vaccines can cause a sudden shock-like collapse, usually

towards the end of the course of treatment." He added that no comment

can be passed in this case without further examination.



--

Communicated by:

ProMED-mail



[According to the WHO 2010 position paper on rabies vaccines, there

are an estimated 20 000 deaths annual attributable to rabies in

India.



There are 2 types of rabies vaccines for humans, nerve tissue and cell

culture vaccines. WHO recommends all countries replace the use of

nerve tissue vaccines with the use of the more efficacious, safer

vaccines developed through cell culture as soon as possible. In the

past, India had been using the neural tissue vaccines but has changed

over to the use of the cell culture vaccines.



The concentrated and purified cell-culture (CCV) and embryonated

egg-based (EEV) rabies vaccines (jointly referred to as CCEEVs) have

proved to be safe and effective in preventing rabies. Nerve tissue

vaccines have been associated with more severe adverse reactions and

are generally more immunogenic than the CCEEVs and are no longer

recommended for use by WHO. CCEEVs contain rabies virus that has been

propagated in cell substrates such as human diploid cells (embryonic

fibroblast cells), fetal rhesus diploid cells, Vero cells (African

green monkey kidney cells), primary Syrian hamster kidney cells,

primary chick embryo cells or embryonated duck eggs. The more recently

developed vaccines that are based on chick embryo cells and Vero cells

have safety and efficacy records comparable to those of the human

diploid cell vaccines and are less expensive.



Following growth in the respective cell cultures (or embryonic egg),

the viral harvest is concentrated, purified, inactivated and

lyophilized. Some of the CCEEVs use human albumin or processed gelatin

as a stabilizer. WHO prequalified rabies vaccines do not use

preservatives such as thimerosal.



Recommendations for post-exposure depend on the type of contact with

the suspected rabid animal. For category I exposure (touching or

feeding animals, licks on intact skin), no prophylaxis is required;

for category II (nibbling of uncovered skin, minor scratches or

abrasions without bleeding), immediate vaccination; and for category

III (single or multiple transdermal bites or scratches, contamination

of mucous membrane with saliva from licks, licks on broken skin,

exposures to bats), immediate vaccination and administration of rabies

immunoglobulin are recommended.



According to WHO data on post rabies vaccines adverse events,

approximately 35-45 percent of recipients develop minor and transient

erythema (redness), pain and/or swelling at the vaccination site,

especially following intradermal booster administration. Mild systemic

events such as transient fever, headache, dizziness and

gastrointestinal symptoms have been observed in 5-15 percent of

vaccinees. More serious adverse events -- mainly allergic or

neurological -- have been noted to rarely occur

().



The above description of the serious adverse events in 2 individuals

vaccinated from the same newly opened vial of vaccine is suggestive of

the possibility of an additive substance used in that vial of vaccine

prior to administration that led to the apparently rapid onset of

chest pain and respiratory distress. As the rabies vaccines are

lyophilized, the possibility of a contaminant or incorrect solution

used in the reconstitution of the vaccine needs to be considered as

well. It is noteworthy that there were other individuals vaccinated

the same day in the same clinic, presumably using the same substance

for reconstitution of the lyophilized vaccine. The possibility of 2

consecutive rare serious allergic reactions is there, but the

probability of that occurring due to chance seems very low (this

moderator was not able to easily find data on the incidence of

post-vaccine allergic reactions; most documents just mention "very

rare").



More information on findings of the investigations into these events

from knowledgeable individuals would be greatly appreciated.



For the HealthMap/ProMED map of India highlighting New Delhi, the

capital city, see . - Mod.MPP]



[see also:

Rabies - India (15): (AP), human, vaccine failure 20110726.2256

Rabies - India (14): (KA), squirrel, human 20110713.2117

Rabies - India (13): (TN) canine, human 20110707.2059

Rabies - India (12): (MA) PEP failure 20110621.1892

Rabies - India (11): (MA) PEP failure 20110620.1884

Rabies - India (07): (AP) canine, human 20110523.1563

Rabies - India (06): (AP) canine, human 20110522.1558

Rabies - India (05): (AP) canine, human 20110518.1506

Rabies - India (04): (AP) canine, human 20110517.1500

Rabies - India (03): (TN), dog control, human 20110421.1249

Rabies - India (02): (MZ) canine control, human exposure

20110407.1088

Rabies - India: (AP) canine, human exposure 20110102.0018

2010

----

Rabies, canine, human - India (03): (MI) 20101018.3780

Rabies - USA: (VA) ex India, 2009 20101003.3585

Rabies, animal, human - India (02): (GA) 20100720.2431

Rabies, animal, human - India: (HR) 20100629.2164

Rabies, canine, human - India: (JD) susp, RFI 20100228.0666

2009

----

Rabies, human, animals - India: (HP), susp. RFI 20091119.3991

Rabies, human, control - India (TN) 20090422.1511

Rabies, human - UAE ex India 20090220.0723

1999

----

Rabies vaccine, reactions - Brazil (Sao Paulo) (02) 19991215.2165

Rabies vaccine, reactions - Brazil (Sao Paulo): RFI 19991203.2121

1997

----

Rabies, human, vaccine allergies (02) 19971129.2375

Rabies, human, vaccine allergies: RFI 19971120.2338]

.................................................sb/mpp/msp/dk

*##########################################################*

************************************************************

ProMED-mail makes every effort to verify the reports that

are posted, but the accuracy and completeness of the

information, and of any statements or opinions based

thereon, are not guaranteed. The reader assumes all risks in

using information posted or archived by ProMED-mail. ISID

and its associated service providers shall not be held

responsible for errors or omissions or held liable for any

damages incurred as a result of use or reliance upon posted

or archived material.

************************************************************

Donate to ProMED-mail. Details available at:



************************************************************

Visit ProMED-mail's web site at .

Send all items for posting to: promed@promedmail.org (NOT to

an individual moderator). If you do not give your full name

name and affiliation, it may not be posted. You may unsub-

scribe at .

For assistance from a human being, send mail to:

.

############################################################

############################################################

No comments:

Post a Comment